Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334595 | 0.93 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL2913941 | 0.91 | PDE10A (0.61) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL898777 | 0.88 | PDE10A (0.47) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL10518603 | 0.88 | CYSLTR1 (0.51) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL538491 | 0.88 | GPBAR1 (0.54) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL19386131 | 0.88 | PDE10A (0.47) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL269680 | 0.88 | PDE10A (0.47) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL8904769 | 0.88 | PDE10A (0.48) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL860157 | 0.86 | KCNH2 (0.58) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL9598037 | 0.86 | CYSLTR1 (0.46) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824585-A | A kind of method that presence of acidic ionic liquid catalyst prepares 1- aryl -2- quinolyl alcohol cpd | 马鞍山市泰博化工科技有限公司 | 2019-05-31 | — | — | CN | disclosed |
| US-6815547-B2 | ANTIMICROBIAL AGENTS EFFECTIVE AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, ENTEROCOCCUS | AVENTIS PHARMA S.A. (FR) | 2004-11-09 | — | — | US | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
| US-6403610-B1 | ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | CYSLTR2 3554/4885CYSLTR1 2761/4885PDE10A 1430/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | CYSLTR2 3554/4885CYSLTR1 2761/4885PDE10A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.